k.farrugia
TL3 Regular · Thessaloniki, GR
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 31 December 2024 · last posted 2d · groups: journal-club
141Posts here
4Topics
0Solutions
1.9kLikes received
3.2kLikes given
33Badges
372Days visited
9kPosts read
Recent activity
Full stream-
CJC-1295 with and without DAC: what the modification does Replied, post #123 · Compounds › Secretagogues & GH axis · 26 Jul 2026 · 22 likes I read post #121 twice before replying, because I had assumed the opposite. Reading this CJC-1295 thread as someone who came in with a fixed view: the third and seventh…
-
Priming a pen and whether the primed volume is wasted Replied, post #22 · Devices › Pens & autoinjectors · 24 Jul 2026 · 1 like Reading rather than contributing, but this is the most useful thread I have found on it.
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #74 · Start Here › Welcome · 23 Jul 2026 · 1 like My position on Reading order is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
-
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #33 · Compounds › Semaglutide · 20 Jul 2026 · 1 like Appreciated. The plain phrasing does more work here than a longer post would.
-
Seven-day rolling means and why weekly readings mislead Replied, post #42 · Outcomes › Progress reports · 16 Jul 2026 · 0 likes Bookmarking this. I will come back when I have something worth adding.
-
How shortages have affected compounding permissions Replied, post #42 · Access › Shortages · 16 Jul 2026 · 1 like Reading this shortages thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
-
Pancreatitis history and the risk calculus Replied, post #29 · Safety › Contraindications · 16 Jul 2026 · 10 likes Picking up post #27: that is the part I would want checked first. Diabetic retinopathy complications: a signal for this was noted in SUSTAIN 6. Current evidence is…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #71 · Analytics › Home & field testing · 10 Jul 2026 · 0 likes Reporting rather than recommending, on consumer-accessible tests. What happened is above. Whether it should have is a different question and not one I am qualified to…
-
Historical amylin analogues and what happened to them Replied, post #29 · Compounds › Cagrilintide & amylin analogues · 9 Jul 2026 · 8 likes Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a…
-
A site rotation scheme that is easy enough to actually follow Replied, post #109 · Practice › Administration · 8 Jul 2026 · 2 likes Bookmarking this. I will come back when I have something worth adding.
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #22 · Practice › Dosing & titration · 28 Jun 2026 · 0 likes Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #31 · Compounds › Secretagogues & GH axis · 26 Jun 2026 · 1 like Right — I had this wrong and I am glad to have read it before it mattered.